HOME >> BIOLOGY >> NEWS
Outcome for acute lymphoblastic leukemia linked to gene expression patterns

A relatively small number of genes are linked to either resistance or sensitivity to four major cancer drugs used to treat acute lymphoblastic leukemia (ALL), suggesting that these genes are key to treatment outcome. This study, by investigators from St. Jude Children's Research Hospital and Erasmus University Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands, is published in the Aug. 4, 2004 issue of the New England Journal of Medicine (NEJM).

The researchers identified four groups of genes, each of which had a characteristic pattern of expression in leukemia cells depending on whether they were sensitive or resistant to four widely used antileukemic agents. Investigators found that the expression pattern of these genes was significantly related to treatment outcome.

The study identified 123 previously unrecognized genes that are associated with resistance to cancer chemotherapy. Only three of these genes had been previously linked to drug resistance. These new genes represent potential targets for new agents that could be developed to overcome resistance to drugs currently used to treat ALL.

Despite the pioneering role of St. Jude in increasing the cure rate of childhood ALL from 4 percent to more than 80 percent during the past 40 years, the cause of failure in the remaining 20 percent of children is largely unknown, according to William E. Evans, Pharm.D., St. Jude scientific director. The current findings could help further reduce the number of failures. Evans is a senior author of the NEJM report.

"We've known for years that certain genetic changes in leukemic cells are associated with a high risk of treatment failure," Evans said. "But we also realized that many children who have an unfavorable genetic subtype of ALL are cured, and many patients whose genetic subtype was considered to be favorable weren't cured. The findings of this study are helping us understand
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
4-Aug-2004


Page: 1 2 3

Related biology news :

1. High Temperature Immediately Following A Stroke Leads To Worse Outcome; Quick Cooling Shown To Have Benefit
2. Surgical Experience Improves Thyroidectomy Outcome
3. Chromosomal Abnormalities Key For Prediting Leukemia Outcome
4. Colorado State Biology Professor Says Fatty Acids, Not Shadow, Determine Outcome Of Groundhog Day Feb. 2
5. Gene profiles could improve acute leukemia diagnosis and lead to better treatments
6. Scientists discover molecular target for treatment of T cell acute lymphoblastic leukemia
7. Bat saliva drug and new MRI techniques offer hope for acute stroke treatment
8. Mutation may help cause acute myeloid leukemia
9. Cox-2 enzyme plays important role regulating acute pancreatitis and associated lung injury
10. UT Southwestern researchers say overdoses of acetaminophen cause most cases of acute liver failure
11. World Trade Center clean-up workers report acute respiratory problems

Post Your Comments:
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... A new report from the Institute of Medicine says ... at least 60 minutes of vigorous or moderate intensity ... half of American youth meet current evidence-based guidelines of ... physical activity daily, according to the report, which was ... for nearly half of their waking hours, the committee ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... 2013 Virobay, Inc. today announced that their ... an important milestone, as Virobay has now initiated a ... cathepsin S inhibitor.   The first Phase ... study designed to evaluate the safety, tolerability, pharmacokinetics and ... "The initiation of this Phase 1 trial ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
(Date:5/23/2013)... During the conduct of research involving ... principles of good clinical practice (GCP) and human ... Lim, Fellow, Clinical Development at Novartis Pharmaceuticals, will ... the International Conference on Harmonization (ICH) Guideline for ... the conduction of clinical trials ,     Apply ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
Cached News: